Black Diamond Therapeutics
Black Diamond Therapeutics (BDTX) is a clinical-stage precision oncology company focused on discovering and developing small-molecule therapies that target oncogenic drivers. The company uses a targeted discovery approach to identify patients whose tumours are driven by specific genetic alterations, aiming for therapies that can offer more selective activity and potentially improved tolerability versus non-targeted treatments. As a smaller-cap biotechnology firm (market cap approximately $225M), progress depends heavily on clinical trial results, regulatory feedback and partnership opportunities. Financial resources, trial enrolment and competitive developments can materially affect prospects. For investors, Black Diamond represents an opportunity-play in precision oncology with asymmetric outcomes: successful trials could materially re-rate the stock, while setbacks could produce significant share volatility. This summary is for educational purposes only and not investment advice; returns are not guaranteed and investors should consider their risk tolerance and seek independent advice.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Black Diamond Therapeutics' stock with a target price of $9.25, indicating significant growth potential.
Financial Health
Black Diamond Therapeutics is generating solid revenue and cash flow, indicating a healthy financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring BDTX
Digital Therapeutics & Prescription Apps
Software is becoming the new medicine. These carefully selected companies are developing FDA-cleared applications that treat everything from mental health to diabetes. With growing insurance reimbursement and massive scalability, these digital treatments represent healthcare's next frontier.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Precision oncology focus
BDTX targets treatments to tumours with specific genetic drivers, which can improve selectivity — though clinical proof is required and outcomes vary.
Clinical catalysts ahead
Trial readouts and regulatory steps can drive sharp share moves, creating opportunity but also heightening volatility and uncertainty.
Funding and competition
Smaller biotechs depend on capital, partnerships and competitive landscape; these factors can materially affect prospects and share performance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
